KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment: 2022-2024

Historic Asset Writedowns and Impairment for Supernus Pharmaceuticals (SUPN) over the last 3 years, with Dec 2024 value amounting to $8.9 million.

  • Supernus Pharmaceuticals' Asset Writedowns and Impairment fell 724.14% to -$239,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year decrease of 63.34%. This contributed to the annual value of $8.9 million for FY2024, which is 55.92% down from last year.
  • Supernus Pharmaceuticals' Asset Writedowns and Impairment amounted to $8.9 million in FY2024, which was down 55.92% from $20.2 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Asset Writedowns and Impairment ranged from a high of $20.2 million in FY2023 and a low of $8.9 million during FY2024.
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $10.4 million (2022), whereas its average is $13.2 million.
  • In the last 5 years, Supernus Pharmaceuticals' Asset Writedowns and Impairment spiked by 93.34% in 2023 and then tumbled by 55.92% in 2024.
  • Yearly analysis of 3 years shows Supernus Pharmaceuticals' Asset Writedowns and Impairment stood at $10.4 million in 2022, then soared by 93.34% to $20.2 million in 2023, then crashed by 55.92% to $8.9 million in 2024.